to treat polymyositis and dermatomyositis (PM/DM), now classified as Idiopathic Inflammatory Myopathy (IIM). This follows the recent Orphan Drug Designation for Restem-L in IIM. . Emerging ...

In January 2025, RESTEM announced that the U.S. FDA granted Fast Track designation for its Restem-L program, using umbilical cord outer lining stem cells (ULSCs) to treat polymyositis and ...

kids.wustl.edu Objectives: To study myopathies with serum antibodies to the signal recognition particle (SRP), an unusual, myositis specific antibody associated syndrome that has not been well ...

Researchers at Johns Hopkins University School of Medicine have identified a subgroup of patients with necrotizing myopathy who have a novel autoantibody specificity that makes them potential ...

Methods: “Myositis Patient Centered Tele-Research (MyPACER)” is a multi-center observational prospective study conducted over 6 months on IIM patients with dermatomyositis (DM), necrotizing myopathy ...

manchester.ac.uk Objectives: There is a known association between myositis and cancer. The risk is greater in dermatomyositis (DM) than polymyositis (PM), although reliable methods to predict cancer ...

kids.wustl.edu OBJECTIVE To evaluate muscle pathology and clinical characteristics in patients with a myopathy and serum antibodies to the Jo-1 antigen (histidyl ... with muscle fibre pathology in ...

However, its usefulness in evaluating muscle lesions in polymyositis and dermatomyositis syndromes (PM/DM) has not been established. Methods 33 patients with PM/DM who had undergone FDG PET were ...

Actress Kapilakshi Malhotra, who rose to fame with her debut in the Telugu film Prema Pipasi, has recently been diagnosed with myositis, according to reports. It is a rare and serious autoimmune ...

program for the treatment of Polymyositis and Dermatomyositis (PM/DM), a rare autoimmune disease, now defined by the FDA as Idiopathic Inflammatory Myopathy (IIM). This is the second regulatory ...

program for the treatment of Polymyositis and Dermatomyositis (PM/DM), a rare autoimmune disease, now defined by the FDA as Idiopathic Inflammatory Myopathy (IIM). This is the second regulatory ...